Abstract: Provided herein are compositions and methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions with chemosensory receptor ligands. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Abstract: Provided herein are methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions comprising chemosensory receptor ligands. Also provided herein are chemosensory receptor ligand compositions and the preparation thereof for the methods of the present invention.

Abstract: Disclosed is a blowing device (10) for forming containers (24) from thermoplastic material preforms. The device (10) includes a blowing nozzle (12) including a bottom outlet opening (28) for a pressurized blowing fluid to leave along a vertical outlet axis (28) and a single duct (14) for supplying the nozzle (12) with blowing fluid that leads into the nozzle (12), via a top supply opening (31), along an axis that is completely radial relative to the outlet axis (A2) of the nozzle (12). The blowing device is characterized in that the upstream end section of the supply duct (14) leads into the nozzle (12) along a branching axis (B) that forms an obtuse angle (a) with the outlet axis (A1) of the nozzle (12) such that the blowing fluid leaving the supply duct (14) is directed downward.

Abstract: Provided herein are methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions comprising chemosensory receptor ligands. Also provided herein are chemosensory receptor ligand compositions and the preparation thereof for the methods of the present invention.

Abstract: Disclosed is a blowing device (10) for forming containers (24) from thermoplastic material preforms. The device (10) includes a blowing nozzle (12) including a bottom outlet opening (28) for a pressurized blowing fluid to leave along a vertical outlet axis (28) and a single duct (14) for supplying the nozzle (12) with blowing fluid that leads into the nozzle (12), via a top supply opening (31), along an axis that is completely radial relative to the outlet axis (A2) of the nozzle (12). The blowing device is characterized in that the upstream end section of the supply duct (14) leads into the nozzle (12) along a branching axis (B) that forms an obtuse angle (a) with the outlet axis (A1) of the nozzle (12) such that the blowing fluid leaving the supply duct (14) is directed downward.

Abstract: Provided herein are methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions comprising chemosensory receptor ligands. Also provided herein are chemosensory receptor ligand compositions and the preparation thereof for the methods of the present invention.

Abstract: Provided herein are methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions comprising chemosensory receptor ligands. Also provided herein are chemosensory receptor ligand compositions and the preparation thereof for the methods of the present invention.

Abstract: Provided herein are compositions and methods for treating diabetes, obesity, and other metabolic diseases, disorders or conditions with chemosensory receptor ligands. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.

Abstract: Compositions and methods for the prevention and treatment of nephropathy, including hypertensive and diabetic nephropathy, and nephropathy associated with insulin resistance and metabolic syndrome are described. Compositions of the invention include a compound that binds to a receptor for the glucagon like peptide-1, an incretin, a glucagon-like peptide-1 (GLP-1), an exendin, or an analog (including an agonist analog), derivative, or variant of any of them.

Abstract: Methods for modulating the effective levels of ghrelin are disclosed. These methods include the use of amylin, amylin agonists and amylin antagonists to regulate the effective levels of ghrelin. Methods for the prevention, treatment, or amelioration of ghrelin-associated diseases or disorders utilizing the methods for modulating ghrelin are also disclosed.

Abstract: The present invention relates generally to the novel use of GLP-1, including analogs, and agonists, to prevent cardiac myocyte apoptosis. The present invention relates to methods for using GLP-1 for the treatment of conditions associated with cardiac myocyte apoptosis. The present invention further relates to improving the efficiency of cardiac myocytes and also to improving cardiac contractility.

Abstract: Compositions and methods for the prevention and treatment of nephropathy, including hypertensive and diabetic nephropathy, and nephropathy associated with insulin resistance and metabolic syndrome are described. Compositions of the invention include a compound that binds to a receptor for the glucagon like peptide-1, an incretin, a glucagon-like peptide-1 (GLP1), an exendin, or an analog (including an agonist analog), derivative, or variant of any of them.